Project details
Isreali cancer treatment company seeks investment
| Project region | Israel |
|---|---|
| Industry | Healthcare |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
| Project highlights | NADAV technology - NDV - Mucus virus |
|---|---|
| Project description |
The Israeli cancer treatment company is developing a new biological / drug platform (NADAV technology) - a proprietary strain based on oncolytic virus NDV, which can target a variety of cancers. A series of in vivo, in vitro and clinical studies on NDV strains, show that NDV strains retain the potential selective and targeted cell death (apoptosis) mechanism of human cancer cells. Another virus named Mucus virus can preferentially replicate and kill cancer cells. For the virus to have oncolytic effect, it must be safe for human beings, only kill cancer cells while retaining normal cells, and genetic stability. The company seeks investment. |
We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.
Have Any Questions?
Reach out to our local experts, we’ll respond within one business day.
Our Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
